Bimekizumab is recommended for treating severe plaque psoriasis in draft NICE guidance, which was developed using a new way to review appraisals.

NICE has today published a new rapid COVID-19 guideline to help healthcare staff identify and treat patients who develop the rare syndrome vaccine-induced immune thrombocytopenia and thrombosis (VITT) after receiving COVID-19 vaccinations.

In a change to current practice the guideline says that the first-line choice of antibiotic for adults for a first episode of mild or moderate C. difficile infection should be oral vancomycin, rather than metronidazole.

Some people who have cholangiocarcinoma are now set to benefit from life-extending treatment pemigatinib after NICE published final draft guidance recommending it.

Following a review of the evidence, NICE has published draft updated guidelines with a new recommendation on the use of progesterone in threatened miscarriage.

NICE has issued final draft guidance which does not recommend the treatment for newly diagnosed high-risk hormone-sensitive metastatic prostate cancer.

Chlormethine gel is recommended in final draft guidance following the agreement of a new commercial discount.

NICE draft draft guidance does not recommend gene therapy OTL-200 for metachromatic leukodystrophy in children, but NICE says it would welcome further discussions between NHS England and the company making the treatment to resolve the uncertainties highlighted by the committee.

Berotralstat is not recommended due to effectiveness uncertainty and cost.

Clinical trial evidence is uncertain and it is unlikely that collecting more data in the Cancer Drugs Fund would resolve the uncertainties, according to the draft guidance.